October 2024
|
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1 <1%: a Pooled Analysis
Peters S….Ramalingam S JTO (IASCL) ✅Take Home: Nivolumab plus ipilimumab with or without chemotherapy significantly improves long-term survival and clinical outcomes compared to chemotherapy alone in patients with metastatic NSCLC and low PD-L1 expression, supporting its use as a first-line treatment. https://www.jto.org/article/S1556-0864(24)02355-4/abstract |
|
Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes
Provencio M…Domine M The Lancet Oncology ✅Take Home The NADIM trial showed that perioperative chemoimmunotherapy significantly improves long-term survival in resectable stage IIIA NSCLC, with a 5-year progression-free survival of 65% and no unexpected long-term toxicities. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2824%2900498-4/fulltext |
|
Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non–Small Cell Lung Cancer Treated With EGFR-tyrosine kinase inhibitors
Sun H…Bashing L JCO (ASCO) ✅Take Home A multicenter phase III trial found that concurrent thoracic radiotherapy (TRT) with EGFR-tyrosine kinase inhibitors (TKIs) significantly improved progression-free survival (17.1 months vs. 10.6 months) and overall survival (34.4 months vs. 26.2 months) in patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer, although it was associated with a higher incidence of severe treatment-related adverse events. https://ascopubs.org/doi/10.1200/JCO.23.02075 |
|
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous Non–Small-Cell Lung Cancer That Responded to First-Line Pembrolizumab Plus Chemotherapy
Hochmair M…Nadal E JTO (IASLC) ✅Take Home The addition of olaparib to pembrolizumab as maintenance therapy in metastatic squamous NSCLC did not significantly improve progression-free or overall survival compared to pembrolizumab plus placebo, with no new safety concerns observed. https://www.jto.org/article/S1556-0864(24)02420-1/abstract |
|
Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer
Chen Z…Lu S JTO (IASLC) ✅Take Home The combination of ivonescimab with etoposide and carboplatin as a first-line treatment for extensive-stage small cell lung cancer demonstrated promising antitumor activity and was well-tolerated, with an overall response rate of 80% despite notable treatment-related adverse events in 60% of patients. https://www.jto.org/article/S1556-0864(24)02421-3/abstract |